Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 29

Results For "President"

2191 News Found

Lupin launches long-acting Risperidone in US
News | November 17, 2025

Lupin launches long-acting Risperidone in US

This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology


AstraZeneca and Sun Pharma partner to expand hyperkalemia treatment in India
News | November 17, 2025

AstraZeneca and Sun Pharma partner to expand hyperkalemia treatment in India

Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names


ALBIS unveils next-gen healthcare materials at COMPAMED 2025
News | November 16, 2025

ALBIS unveils next-gen healthcare materials at COMPAMED 2025

ALBIS will present a selection of advanced materials from its broad healthcare portfolio


ImmunoScape inks agreement with Cue Biopharma to launch next-gen cancer immunotherapy
Biopharma | November 16, 2025

ImmunoScape inks agreement with Cue Biopharma to launch next-gen cancer immunotherapy

The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies


Kaiser Permanente’s study highlights power of genetics in preventing heart disease
R&D | November 14, 2025

Kaiser Permanente’s study highlights power of genetics in preventing heart disease

Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD


Transition Bio and Voyager Therapeutics forge strategic collaboration to target ALS, FTD
Biopharma | November 14, 2025

Transition Bio and Voyager Therapeutics forge strategic collaboration to target ALS, FTD

The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology


SpyGlass Pharma reports promising clinical trial results for glaucoma therapy
Biopharma | November 14, 2025

SpyGlass Pharma reports promising clinical trial results for glaucoma therapy

The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance


AstraZeneca's Baxdrostat achieves breakthrough blood pressure reductions in Phase III Bax24 trial
Clinical Trials | November 12, 2025

AstraZeneca's Baxdrostat achieves breakthrough blood pressure reductions in Phase III Bax24 trial

Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo